KYNTHEUM APPROVED IN THE EU FOR THE TREATMENT OF ADULTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS
Kyntheum is the first and only fully-human monoclonal antibody that selectively targets the IL-17 receptor subunit A on skin cells.
Ämnen: Sjukdomar
-
-
Faslodex (fulvestrant) receives positive CHMP opinion for use in 1st-line hormone receptor-positive advanced breast cancer
AstraZeneca today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion, recommending the marketing authorisation of Faslodex.
-
Upptäckter som räddar liv – årets tema för Sommarforskarskolan
Måndag 19 juni öppnas portarna till årets upplaga av AstraZenecas sommarforskarskola och de kommande två veckorna kommer 52 elever i åldrarna 14–17 år få testa på inspirerande och lärorika experiment i laboratoriesalarna på KTH i Stockholm.
-
Nordisk registerstudie på ADA: Behandling av typ 2-diabetes med SGLT-2-hämmare, jämfört med andra glukossänkande läkemedel, förknippas med en minskad risk för förtida död och hjärtsvikt
Resultat från den nordiska delen av observationsstudien CVD-REAL, presenterades vid ADA, den 11 juni. Resultaten visar att behandling av typ 2-diabetes med SGLT2-hämmare i klinisk verklighet är associerad med en signifikant minskad risk för kardiovaskulära insjuknanden, särskilt med dödlig utgång, jämfört med andra glukossänkande läkemedel, även hos patienter utan känd hjärt-kärlsjukdom.
-
AstraZeneca presents new data underpinning safety profile and Real-World CV outcomes of Farxiga at ADA 2017
Comprehensive updated analysis provides valuable evidence on the safety profile of Farxiga, including no imbalance in lower-limb amputations New analyses from CVD-REAL examine reductions in CV events for SGLT-2 inhibitors, including Farxiga in patients with and without CV disease versus DPP-4 inhibitors
-
AstraZeneca to present scientific advances in Cardiovascular and Metabolic Diseases at 2017 ADA Scientific Sessions
AstraZeneca and its global biologics research and development arm, MedImmune, will present the latest research from the Company’s Cardiovascular and Metabolic Diseases (CVMD) therapy area, including for Farxiga (dapagliflozin) and Bydureon(exenatide extended-release), with more than 50 abstracts at the American Diabetes Association’s (ADA) 77th Scientific Sessions in San Diego, USA, 9-13 June 2017
-
AstraZeneca enters agreement with Grünenthal to divest rights to migraine treatment Zomig
AstraZeneca today announced that it has entered an agreement with Grünenthal for the global rights to Zomig(zolmitriptan) outside Japan
-
Lynparza significantly reduces the risk of disease worsening or death in patients with BRCA-mutated metastatic breast cancer
AstraZeneca today presented positive results from its Phase III OlympiAD trial that showed a statistically-significant and clinically-meaningful improvement in progression-free survival (PFS) for patients treated with Lynparza (olaparib) tablets (300mg twice daily), compared to treatment with physician’s choiceof a standard of care chemotherapy.
-
AstraZeneca delivers new data on expanding portfolio of cancer medicines at 2017 American Society of Clinical Oncology (ASCO) Annual Meeting
AstraZeneca, along with its global biologics research and development arm, MedImmune, will demonstrate how it is rapidly delivering on the Company’s science-led strategy for transformational cancer medicine development at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting.
-
Bydureon EXSCEL trial meets primary safety objective in type-2 diabetes patients at wide range of cardiovascular risk
AstraZeneca today announced top-line results from the Phase IIIb/IV EXSCEL (EXenatide Study of Cardiovascular Event Lowering) trial.
-
Phase III Zonda trial for benralizumab shows ability to reduce oral steroid use in severe asthma patients
Results from the Phase III ZONDA trial presented at the American Thoracic Society (ATS) 2017 International Congress demonstrated that adding benralizumab to standard of care allowed patients dependent on OCS to significantly reduce or discontinue steroids while maintaining asthma control.
-
AstraZeneca enters agreement with Recordati for Seloken in Europe
AstraZeneca announced today that it has entered into an agreement with Recordati S.p.A (Recordati) for the commercial rights to Seloken/Seloken ZOK
-
AstraZeneca to present scientific advancements from growing respiratory portfolio at the American Thoracic Society conference 2017
AstraZeneca and its global biologics research and development arm, MedImmune, will present new data from its growing respiratory portfolio and pipeline at the 113th annual conference of the American Thoracic Society (ATS) in Washington, DC, USA, 19-24 May 2017
-
Stipendium till Katalin Dobra
Idag tilldelas Universitetslektor Katalin Dobra, verksam vid Karolinska Institutet och Överläkare vid Karolinska Universitetssjukhuset, Svensk Förening för Patologis (SvFP), stipendie för 2017. Stipendiet uppmärksammar personer som bidrar med betydande insatser inom molekylärpatologisk diagnostik och har instiftats av Svensk Förening för Patologi (SvFP) och AstraZeneca.
-
Imfinzi significantly reduces the risk of disease worsening or death in the phase III pacific trial for stage III unresectable lung cancer
Imfinzi met a primary endpoint of statistically-significant and clinically-meaningful progression-free survival (PFS) in ‘all-comer’ patients with locally-advanced, unresectable (Stage III) non-small cell lung cancer in a planned interim analysis
-
AstraZeneca provides update on STRATOS 1 phase III trial of tralokinumab in severe, uncontrolled asthma
Tralokinumab did not meet its primary endpoint of a significant reduction in the annual asthma exacerbation rate
Second pivotal Phase III trial STRATOS 2 is ongoing with results expected in second half of 2017
AstraZenecaand MedImmune, its global biologics research and development arm, today announced that tralokinumab, an anti-interleukin-13 (IL-13) human monoclonal antibody, did not meet i -
Lungcancerstipendium till Dr Mikael Johansson
Idag tilldelas Överläkare Mikael Johansson, verksam vid Cancercentrum, Norrlands Universitetssjukhus, SLUSG-stipendiet 2017. Stipendiet har instiftats av Svenska Lungcancerstudiegruppen (SLUSG) och AstraZeneca och uppmärksammar personer som bidrar med betydande insatser inom lungcancerområdet.
-
AstraZeneca PLC:s resultatrapport för första kvartalet 2017
En positiv start med fortsatt nyhetsflöde kring vår forskningsportfölj i det som har potential att bli ett avgörande år för bolaget
-
Tagrisso receives full approval in the EU
Full approval follows Tagrisso’s expedited Conditional Marketing Authorisation as first-in-class medicine for patients with locally-advanced or metastatic EGFR T790M mutation-positive non-small cell lung cancer
-
Tagrisso (osimertinib) receives US FDA full approval
Conversion from accelerated to full approval confirms the potential of Tagrissoto become standard of care in the US Approval based on Phase III AURA3 trial thatdemonstrated significant improvement in progression-free survival with Tagrisso as compared to chemotherapy
Visa mer
Loading...